Supplementary Tables S1, S2 and Figures S1-S5 from A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III &lt;i&gt;PIK3CA&lt;/i&gt;-Mutant ER-Positive and HER2-Negative Breast Cancer